

Antithrombotic Therapy for VTE Disease

Chest

160, e545-e608

DOI: [10.1016/j.chest.2021.07.055](https://doi.org/10.1016/j.chest.2021.07.055)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Venous thromboembolism: Recent advancement and future perspective. Journal of Cardiology, 2022, 79, 79-89.	1.9	19
2	Initial experience and early outcomes of the management of acute pulmonary embolism using the FlowTrier mechanical thrombectomy device. Journal of Cardiovascular Surgery, 2021, , .	0.6	1
3	The role of the PERT team in 2021. Thrombosis Update, 2022, 6, 100092.	0.9	6
4	Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics. Frontiers in Cardiovascular Medicine, 2021, 8, 787235.	2.4	4
5	Clinical Management of Thrombotic Antiphospholipid Syndrome. Journal of Clinical Medicine, 2022, 11, 735.	2.4	11
6	Management and Outcomes of Adults Diagnosed with Acute Pulmonary Embolism in Primary Care: Community-Based Retrospective Cohort Study. Journal of General Internal Medicine, 2022, , 1.	2.6	8
7	Anticoagulants in the treatment of superficial vein thrombosis of lower limbs: possibilities and limitations. Atherothrombosis, 2022, 11, 94-102.	0.3	0
8	Prevalence, Characteristics, and Outcomes of Emergency Department Discharge Among Patients With Sepsis. JAMA Network Open, 2022, 5, e2147882.	5.9	10
9	Expert Recommendations on the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) from India: Current Perspective and Future Direction. Cardiology and Therapy, 2022, 11, 49-79.	2.6	2
10	Pharmacological and interventional management of pulmonary embolism: where do we stand?. Future Cardiology, 2022, 18, 191-206.	1.2	3
11	Inherited Thrombophilia in the Era of Direct Oral Anticoagulants. International Journal of Molecular Sciences, 2022, 23, 1821.	4.1	14
12	Unmet clinical needs in the prevention and treatment of cancer-associated venous thromboembolism. Trends in Cardiovascular Medicine, 2023, 33, 336-343.	4.9	6
13	Subsegmental Pulmonary Embolism: To Treat or Not to Treat?. , 2022, 19, .		0
14	Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210829.	1.7	7
15	Antithrombotic Therapy After Venous Interventions: <i>AJR</i> Expert Panel Narrative Review. American Journal of Roentgenology, 2022, 219, 175-187.	2.2	8
16	Asymptomatic pulmonary thromboembolism diagnosed based on prolonged fever after gastric cancer surgery: A case report with literature review. International Journal of Surgery Case Reports, 2022, 92, 106836.	0.6	0
17	The utility of hereditary thrombophilia testing among patients with lower extremity deep vein thrombosis.. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2022, , .	1.6	0
18	Rebuttal From Dr David Jimenez etÂal. Chest, 2022, 161, 1453-1455.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Rebuttal From Dr Tritschler etÂal. Chest, 2022, , .	0.8	0
20	Complications of Autoimmune Hemolytic Anemia. Hematology/Oncology Clinics of North America, 2022, 36, 353-363.	2.2	2
21	Pulmonary embolism management in the emergency department: part 2. Emergency Medicine Journal, 2023, 40, 69-75.	1.0	4
22	Incidence and clinical impact of bleeding events in older patients with acute venous thromboembolism. Blood Advances, 2023, 7, 205-213.	5.2	2
24	Thrombotic burden, D-dimer levels and complete compression ultrasound for diagnosis of acute symptomatic deep vein thrombosis of the lower limbs. Thrombosis Research, 2022, 213, 163-169.	1.7	1
25	Effectiveness and safety of extended oral anticoagulant therapy in patients with venous thromboembolism: a retrospective cohort study. Clinical Pharmacology and Therapeutics, 2022, , .	4.7	5
26	Anticoagulant Prescriptions Provided in US Ambulatory Practice, 2014 to 2016. Journal of General Internal Medicine, 2022, , 1.	2.6	0
27	Interventional Therapies for Acute Pulmonary Embolism. Surgical Clinics of North America, 2022, 102, 429-447.	1.5	5
28	Is catheter-based foam sclerotherapy more effective than direct foam sclerotherapy when combined with high ligation for the treatment of primary great saphenous vein incompetence?. Vascular, 2022, , 170853812210948.	0.9	0
32	Subsegmental pulmonary embolism and anticoagulant therapy: the impact of clinical context. Internal Medicine Journal, 2023, 53, 1435-1443.	0.8	2
33	Factor XI Inhibition for the Prevention of Venous Thromboembolism: An Update on Current Evidence and Future perspectives. Vascular Health and Risk Management, 0, Volume 18, 359-373.	2.3	25
34	Cancer-Associated Deep Vein Thrombosis: Insights from Randomized Trials and Real-Life Practice. Flebologiya, 2022, 16, 156.	1.0	1
35	Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. American Heart Journal, 2022, 251, 43-53.	2.7	59
36	Sustainability of a Clinical Decision Support Intervention for Outpatient Care for Emergency Department Patients With Acute Pulmonary Embolism. JAMA Network Open, 2022, 5, e2212340.	5.9	10
37	Antithrombotic Therapy for Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2022, 327, 2141.	7.4	3
38	Anesthetic management for intraoperative acute pulmonary embolism during inferior vena cava tumor thrombus surgery: A case report. World Journal of Clinical Cases, 2022, 10, 5111-5118.	0.8	0
39	SCAI Guidelines for the Management of Patent Foramen Ovale. , 2022, 1, 100039.		28
40	Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease. Journal of Thrombosis and Haemostasis, 2022, 20, 1910-1919.	3.8	12

#	ARTICLE	IF	CITATIONS
41	Physician perceptions and use of reduced-dose direct oral anticoagulants for extended phase venous thromboembolism treatment. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12740.	2.3	1
42	Concomitant post-traumatic ocular and cerebral fat embolism syndrome and thrombotic pulmonary embolism. Medicine (United States), 2022, 101, e29331.	1.0	0
43	Extended Anticoagulation After Pulmonary Embolism: A Multicenter Observational Cohort Analysis. Journal of the American Heart Association, 2022, 11, .	3.7	5
44	Cerebrovascular Complications of COVID-19 Disease in Children: A Single-Center Case Series. Pediatric Neurology, 2022, 134, 18-24.	2.1	4
45	Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH AC Registry): A Nationwide Prospective Cohort Study in Japan. SSRN Electronic Journal, 0, , .	0.4	0
46	Direct Oral Anticoagulants for Anticoagulation after Initial Management of Venous Thromboembolism. Annals of Phlebology, 2022, 20, 9-14.	0.1	0
47	The Ottawa Score Performs Poorly to Identify Cancer Patients at High Risk of Recurrent Venous Thromboembolism: Insights from the TROPIQUE Study and Updated Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 3729.	2.4	1
48	Type of Oral Anticoagulant and Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for VTEâ€”Reply. JAMA - Journal of the American Medical Association, 2022, 328, 79.	7.4	0
49	D-dimer: old dogmas, new (COVID-19) tricks. Clinical Chemistry and Laboratory Medicine, 2023, 61, 841-850.	2.3	17
50	Good practice statements for antithrombotic therapy in the management of COVIDâ€”19: Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2022, 20, 2226-2236.	3.8	23
51	Type of Oral Anticoagulant and Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for VTE. JAMA - Journal of the American Medical Association, 2022, 328, 78.	7.4	0
52	Prognostic role of serial electrocardiographic changes in patients with acute pulmonary embolism. Data from the Italian Pulmonary Embolism Registry. Thrombosis Research, 2022, 217, 15-21.	1.7	7
53	Antiplatelet agents for the treatment of deep venous thrombosis. The Cochrane Library, 2022, 2022, .	2.8	9
54	A review of inferior vena cava filters. British Journal of Radiology, 2023, 96, .	2.2	8
55	Recurrence after stopping anticoagulants in women with combined oral contraceptiveâ€”associated venous thromboembolism: A systematic review and <scp>metaâ€”analysis</scp>. British Journal of Haematology, 2022, 199, 130-142.	2.5	5
56	From “3â€”months to forever â€” oral contraceptives, venous thrombosis and duration of anticoagulation. A challenging decision. British Journal of Haematology, 0, , .	2.5	0
57	Risk stratification and treatment of pulmonary embolism with intermediate-risk of mortality. Current Opinion in Pulmonary Medicine, 2022, 28, 375-383.	2.6	2
59	Catheter-related thrombosis (CRT) in patients with solid tumors: a narrative review and clinical guidance for daily care. Supportive Care in Cancer, 2022, 30, 8577-8588.	2.2	6

#	ARTICLE	IF	CITATIONS
60	Evaluating cardiopulmonary function following acute pulmonary embolism. Expert Review of Cardiovascular Therapy, 2022, 20, 747-760.	1.5	1
61	An Update on the Management of Acute High-Risk Pulmonary Embolism. Journal of Clinical Medicine, 2022, 11, 4807.	2.4	9
62	Unprovoked Submassive Saddle Pulmonary Embolism in an Adult Male After Pfizer COVID-19 Vaccination. Cureus, 2022, , .	0.5	0
63	A case of venous thromboembolism caused by protein C deficiency due to a novel gene mutation. Journal of Cardiology Cases, 2022, 26, 360-363.	0.5	3
64	Catheter-directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute pulmonary embolism. The Cochrane Library, 2022, 2022, .	2.8	8
65	The Incidence, Risk Factors, Characteristics and Prognosis of Recurrent Deep Venous Thrombosis in the Contralateral Lower Extremity. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2022, , .	1.6	0
66	Efficacy and safety of direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: A systematic review and Bayesian network meta-analysis. Medicina Clínica, 2023, 160, 245-252.	0.6	2
67	Bioequivalence and Pharmacokinetic Study of 2 Edoxaban Tablets in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development, 2022, 11, 1440-1446.	1.6	1
68	Systematic search for the UBA1 mutation in men after a first episode of venous thromboembolism: A monocentric study. Journal of Thrombosis and Haemostasis, 2022, 20, 2697-2699.	3.8	8
69	Long-term clinical outcomes in older patients with acute venous thromboembolism who have renal impairment. Thrombosis Research, 2022, 218, 64-71.	1.7	1
70	Trends in management and outcomes of pulmonary embolism with a multidisciplinary response team. Journal of Thrombosis and Thrombolysis, 2022, 54, 449-460.	2.1	7
71	Evolving Knowledge on Primary and Secondary Prevention of Venous Thromboembolism in Carriers of Hereditary Thrombophilia: A Narrative Review. Seminars in Thrombosis and Hemostasis, 0, , .	2.7	0
72	Subclavian Effort Thrombosis: Pathophysiology, Diagnosis, and Management. Seminars in Interventional Radiology, 2022, 39, 304-311.	0.8	1
73	Intermediate-Risk Pulmonary Embolism: A Review of Contemporary Diagnosis, Risk Stratification and Management. Medicina (Lithuania), 2022, 58, 1186.	2.0	6
75	Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures. Pharmacotherapy, 2022, 42, 780-791.	2.6	7
77	Anticoagulant use and associated outcomes in older patients receiving home palliative care: a retrospective cohort study. Cmaj, 2022, 194, E1198-E1208.	2.0	4
78	Evolving Knowledge on Primary and Secondary Prevention of Venous Thromboembolism in Carriers of Hereditary Thrombophilia: A Narrative Review. Seminars in Thrombosis and Hemostasis, 0, , .	2.7	2
79	Thrombolysis versus unfractionated heparin for hemodynamically stable patients with pulmonary embolism: a systematic review and meta-analysis. Russian Journal of Cardiology, 2022, 27, 5120.	1.4	1

#	ARTICLE	IF	CITATIONS
80	A Description of Apixaban Dosing Patterns for Treatment or Prevention of Thrombotic Events in Hospitalized Patients on Dialysis. Hospital Pharmacy, 0, , 001857872211153.	1.0	2
81	Concomitant Deep Vein Thrombosis in Cancer Patients with Unsuspected Pulmonary Embolism. Cancers, 2022, 14, 4510.	3.7	0
82	Should ultrasound evaluation for catheter-related thrombosis always be required before PICC removal?. Journal of Vascular Access, 0, , 112972982211259.	0.9	0
83	Dual Anticoagulation With Warfarin and Apixaban: A Case Report. Cureus, 2022, , .	0.5	0
84	Management of Massive Pulmonary Embolism. International Journal of Angiology, 2022, 31, 194-197.	0.6	0
85	Direct oral to parenteral anticoagulant transitions: Role of factor Xa inhibitorâ€™specific antiâ€™X concentrations. Pharmacotherapy, 2022, 42, 768-779.	2.6	0
86	Dilemmas in the Choice of Adequate Therapeutic Treatment in Patients with Acute Pulmonary Embolismâ€™From Modern Recommendations to Clinical Application. Pharmaceuticals, 2022, 15, 1146.	3.8	1
87	Muscular Calf Vein Thrombosis Is Associated With Increased 30-Day Mortality But Not 90-Day Mortality in Older Patients With Hip Fracture. American Journal of Cardiology, 2022, 184, 141-146.	1.6	3
89	Identification of outcomes in clinical studies of interventions for venous thromboembolism in nonâ€™pregnant adults. Journal of Thrombosis and Haemostasis, 2022, 20, 2204-2206.	3.8	0
90	Deep Venous Thrombosis. Annals of Internal Medicine, 2022, 175, ITC129-ITC144.	3.9	31
91	Protecting patients during a shortage of thrombolytic agents. Lancet, The, 2022, 400, 1193-1194.	13.7	2
92	Comparative Effectiveness and Safety of Extended Anticoagulant Therapy among Medicare Beneficiaries with Venous Thromboembolism. Clinical and Translational Science, 0, , .	3.1	1
93	Complications of Vascular Disease. Anesthesiology Clinics, 2022, 40, 587-604.	1.4	0
94	Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review. Clinical Pharmacokinetics, 2022, 61, 1677-1695.	3.5	3
95	Synoptic reporting accuracy for computed tomography pulmonary arteriography among patients suspected of pulmonary embolism. Journal of the American College of Emergency Physicians Open, 2022, 3, .	0.7	1
96	Prescribing Trends of Oral Anticoagulants from 2010 to 2020 in Shanghai, China: A Retrospective Study. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962211325.	1.7	4
97	Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project. Life, 2022, 12, 1657.	2.4	1
99	Utilization trends and outcomes of catheter-directed thrombolysis for pulmonary embolism in the US by race/ethnicity. Journal of Thrombosis and Thrombolysis, 2022, 54, 675-685.	2.1	2

#	ARTICLE	IF	CITATIONS
100	What Is the Efficacy of Catheter-Directed Thrombolysis Versus Systemic Anticoagulation Alone for Submassive Pulmonary Embolism?. Annals of Emergency Medicine, 2022, , .	0.6	0
101	Safety and Efficacy of Rivaroxaban as Extended-Phase Anticoagulation in Patients with Cancer and Venous Thromboembolism: A Preliminary Data Analysis from the Mac Project. Life, 2022, 12, 1725.	2.4	1
102	Warfarin Is the Preferred Therapy for Patients With Thrombotic APS. Journal of the American College of Cardiology, 2023, 81, 31-33.	2.8	1
103	Standardization of Pulmonary Embolism Evaluation and Management Through Implementation of a Pulmonary Embolism Response Team: A Single-Center Experience at Brooke Army Medical Center. Military Medicine, 0, , .	0.8	0
104	Dilemmas Related to Direct-Acting Oral Anticoagulant Administration in Patients With Extreme Obesity. Annals of Pharmacotherapy, 0, , 106002802211304.	1.9	0
105	Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patients. Experimental Hematology and Oncology, 2022, 11, .	5.0	1
106	Advancing anticoagulation stewardship: A call to action for stewardship from the US-based anticoagulation forum. Thrombosis Update, 2022, , 100125.	0.9	3
107	Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis. Vascular Health and Risk Management, 0, Volume 18, 793-807.	2.3	2
108	Long-Term Management of Pulmonary Embolism: A Review of Consequences, Treatment, and Rehabilitation. Journal of Clinical Medicine, 2022, 11, 5970.	2.4	1
109	Machine learning algorithm as a prognostic tool for venous thromboembolism in allogeneic transplant patients. Transplantation and Cellular Therapy, 2023, 29, 57.e1-57.e10.	1.2	0
110	Multidisciplinary Care for the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer-Associated Thrombosis (CAT): Impact of Educational Interventions on CAT-Related Events and on Patientsâ€™ and Cliniciansâ€™ Awareness. Life, 2022, 12, 1594.	2.4	3
111	Length of Anticoagulation in Provoked Venous Thromboembolism: A Multicenter Study of How Realâ€‘World Practice Mirrors Guideline Recommendations. Journal of the American Heart Association, 2022, 11, .	3.7	1
112	Contemporary Perioperative Management of Direct Oral Anticoagulants. Advances in Anesthesia, 2022, 40, 93-109.	0.9	0
113	Proportion of Patients on Warfarin Therapy Who Are Eligible for Conversion to a Direct Oral Anticoagulant in the Setting of COVID-19. Annals of Pharmacotherapy, 0, , 106002802211368.	1.9	0
115	Use of YEARS Algorithm in Military Health Care Beneficiaries to Evaluate Use of Computed Tomography Pulmonary Angiography. Military Medicine, 0, , .	0.8	0
116	Deep vein thrombosis symptoms and 30-day mortality in acute pulmonary embolism. European Journal of Internal Medicine, 2023, 108, 43-51.	2.2	1
117	Performance Status and Long-Term Outcomes in Cancer-Associated Pulmonary Embolism. JACC: CardioOncology, 2022, 4, 507-518.	4.0	6
118	Effectiveness and safety of rivaroxaban in patients with venous thromboembolism and active cancer: A subanalysis of the J'xactly study. Journal of Cardiology, 2023, 81, 268-275.	1.9	0

#	ARTICLE	IF	CITATIONS
119	Comparison of bleeding following gastrointestinal endoscopic biopsy in patients treated with and without direct oral anticoagulants. <i>Endoscopy International Open</i> , 2023, 11, E52-E59.	1.8	2
120	A Review of the Past, Present and Future of Cancer-associated Thrombosis Management. <i>Heart International</i> , 2022, 16, 117.	1.4	2
122	COVID-19 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: THE RISK OF THROMBOEMBOLIC EVENTS AND CURRENT OPTIONS FOR ANTITHROMBOTIC PROPHYLAXIS. , 2022, , 88-103.	0.1	0
123	Upper Extremity Deep Venous Thrombosis: Etiologies, Diagnosis, and Updates in Therapeutic Strategies. <i>Seminars in Interventional Radiology</i> , 2022, 39, 475-482.	0.8	0
124	Effectiveness and safety of the direct oral anticoagulant in acute distal deep vein thrombosis: From the prospective multicenter observational study, Jâ€™xactly, in Japan. <i>Phlebology</i> , 0, , 026835552211413.	1.2	0
125	Predictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad TromboembÃ³lica registry. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	0
126	Catheter-Directed Interventions for the Treatment of Lower Extremity Deep Vein Thrombosis. <i>Life</i> , 2022, 12, 1984.	2.4	5
127	Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery. <i>The Cochrane Library</i> , 2022, 2022, .	2.8	5
128	Mechanical thrombectomy versus catheter directed thrombolysis in patients with pulmonary embolism: A multicenter experience. <i>Catheterization and Cardiovascular Interventions</i> , 2023, 101, 140-146.	1.7	4
129	Risk factors of venous thromboembolism after incisional ventral hernia repair. <i>Hernia: the Journal of Hernias and Abdominal Wall Surgery</i> , 0, , .	2.0	2
130	The incidence of deep vein thrombosis after anterior cruciate ligament reconstruction: An analysis using routine ultrasonography of 260 patients. <i>PLoS ONE</i> , 2022, 17, e0279136.	2.5	0
131	Chemotherapy Induced Cardiotoxicity: A State of the Art Review on General Mechanisms, Prevention, Treatment and Recent Advances in Novel Therapeutics. <i>Current Problems in Cardiology</i> , 2023, 48, 101591.	2.4	11
132	A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry. <i>Medicina (Lithuania)</i> , 2023, 59, 181.	2.0	0
133	Safety of discontinuation of anticoagulants after venous thromboembolism: whether D-dimer level should be taken into account?. <i>Atherothrombosis</i> , 2023, 12, 22-31.	0.3	0
134	Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study. <i>BMC Musculoskeletal Disorders</i> , 2023, 24, .	1.9	6
135	A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK. <i>Current Medical Research and Opinion</i> , 2023, 39, 483-495.	1.9	0
136	Venous thromboembolism associated with estrogenâ€™containing contraceptives versus any hormonal risk factor: aÂˆcomparison of recurrence rates. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 175-178.	3.8	0
137	Endovascular Venous Interventions - A State-of-the-Art Review. <i>Current Problems in Cardiology</i> , 2023, 48, 101534.	2.4	3

#	ARTICLE	IF	CITATIONS
138	Unusual cause of retroperitoneal hemorrhage: Acute deep vein thrombosis. Journal of Cardiology Cases, 2023, 27, 165-167.	0.5	1
139	Interesting case of incidental diagnosis of pulmonary embolism by endobronchial ultrasonography. BMJ Case Reports, 2022, 15, e253943.	0.5	0
140	Systemic thrombolytic and ultrasound-assisted catheter-directed thrombolysis for treatment of acute pulmonary embolism: a 7-year, multicenter experience. Journal of Thrombosis and Thrombolysis, 0, , .	2.1	1
141	Thrombophilia and outcomes of venous thromboembolism in older patients. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100015.	2.3	0
142	Antithrombotic therapy in COVID-19 patients. Obstetrics, Gynecology and Reproduction, 2023, 16, 718-731.	0.5	1
143	Treatment and prevention of cancer-associated thrombosis in the Netherlands: A national survey. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100057.	2.3	2
144	Long-term Anticoagulation with Apixaban in Patients with Cerebral Venous Thrombosis. Clinical and Applied Thrombosis/Hemostasis, 2023, 29, 107602962211295.	1.7	2
145	Inpatient pharmacyâ€driven antithrombosis stewardship efforts on warfarin to direct oral anticoagulant conversions. JACCP Journal of the American College of Clinical Pharmacy, 2023, 6, 231-240.	1.0	0
146	Comparison of endovenous laser ablation and conservative treatment in acute thrombophlebitis of the varicose great saphenous vein: rationale, design and first results of clinical trial. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 21, 3461.	1.4	2
147	Management and outcomes of calf deep vein thrombosis in patients with contraindication to full anticoagulation due to bleeding. International Angiology, 2023, 42, .	0.9	1
148	Acute phase characteristics and long-term complications of pulmonary embolism in COVID-19 compared to non-COVID-19 cohort: a large single-centre study. BMC Pulmonary Medicine, 2023, 23, .	2.0	2
149	Weight-adjusted dosing of tinzaparin for thromboprophylaxis in obese medical patients. Research and Practice in Thrombosis and Haemostasis, 2023, , 100054.	2.3	0
150	Nitrous oxide misuse: a clue not to be missed in young patients with venous thromboembolism. Clinical Medicine, 2023, 23, 170-172.	1.9	1
151	Effectiveness and safety of catheter-directed thrombolysis in conjunction with percutaneous mechanical thrombectomy for acute iliofemoral deep vein thrombosis: A meta-analysis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2023, 11, 843-853.e2.	1.6	2
152	Reduced-Dose Thrombolysis in Acute Pulmonary Embolism A Systematic Review. Angiology, 2024, 75, 208-218.	1.8	3
153	Is it necessary to wear compression stockings and how long should they be worn for preventing post thrombotic syndrome? A meta-analysis of randomized controlled trials. Thrombosis Research, 2023, 225, 79-86.	1.7	2
154	High-risk pulmonary embolism in the intensive care unit. Intensive Care Medicine, 2023, 49, 579-582.	8.2	6
155	Efficacy and safety of direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: A systematic review and Bayesian network meta-analysis. Medicina Clínica (English) Tj ETQq1 1oQ784314rgBT /Ove		

#	ARTICLE	IF	CITATIONS
156	The oft-overlooked cardiovascular complications of inflammatory bowel disease. Expert Review of Clinical Immunology, 2023, 19, 375-391.	3.0	5
157	Antithrombotische Therapie. , 2022, , 233-263.		0
158	Percutaneous Management of High-Risk Pulmonary Embolism. Circulation: Cardiovascular Interventions, 2023, 16, .	3.9	7
159	Lack of Funding for Direct-Acting Oral Anticoagulants for the Treatment of Pulmonary Embolism in Spain: Why and Until When. Archivos De Bronconeumologia, 2023, , .	0.8	0
160	Chemoprophylaxis and Management of Venous Thromboembolism in Microvascular Surgery. Seminars in Plastic Surgery, 2023, 37, 057-072.	2.1	1
161	DOAC compared with warfarin for VTE in patients with obesity: a retrospective cohort study conducted through the VENUS network. Journal of Thrombosis and Thrombolysis, 2023, 55, 685-690.	2.1	5
162	<scp>Warfarinâ€Rifampinâ€Gene</scp> (WARIFâ€G) Interaction: AÂRetrospective, Genetic, <scp>Caseâ€Control</scp> Study. Clinical Pharmacology and Therapeutics, 2023, 113, 1150-1159.	4.7	1
163	Direct Oral Anticoagulants in Obese Patients with Venous Thromboembolism: Results of an Expert Consensus Panel. American Journal of Medicine, 2023, 136, 523-533.	1.5	6
164	Saddle Pulmonary Embolism and Atrial Fibrillation. Clinical Cases in Cardiology, 2023, , 29-34.	0.0	0
166	Barriers and facilitators to interhospital transfer of acute pulmonary embolism: An inductive qualitative analysis. Frontiers in Medicine, 0, 10, .	2.6	2
167	In Situ Pulmonary Arterial Thrombosis: Literature Review and Clinical Significance of a Distinct Entity. American Journal of Roentgenology, 2023, 221, 57-68.	2.2	6
168	Updated Trends in Inferior Vena Cava Filter Use by Indication in the United States After Food and Drug Administration Safety Warnings: A Decade Analysis From 2010 to 2019. Journal of Endovascular Therapy, 0, , 152660282311560.	1.5	1
169	Coagulopathy and Emergent Reversal of Anticoagulation. Anesthesiology Clinics, 2023, 41, 249-261.	1.4	0
170	Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among patients with recurrent venous thromboembolism. Clinical and Translational Science, 2023, 16, 946-954.	3.1	0
171	Clinical course and treatment of incidentally detected splanchnic vein thrombosis: an individual patient data meta-analysis. Journal of Thrombosis and Haemostasis, 2023, 21, 1592-1600.	3.8	5
172	Fake-news-free evidence-based communication for proper vein-lymphatic disease management. International Angiology, 2023, 42, .	0.9	1
173	Anatomic distribution of lower extremity deep venous thrombosis is associated with an increased risk of pulmonary embolism: A 10-year retrospective analysis. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	3
174	Trends in the Use of Oral Anticoagulants for Adults With Venous Thromboembolism in the US, 2010-2020. JAMA Network Open, 2023, 6, e234059.	5.9	8

#	ARTICLE	IF	CITATIONS
176	Incidence and prognosis of superficial vein thrombosis during pregnancy and the post-partum period: a Danish nationwide cohort study. <i>Lancet Haematology</i> , 2023, 10, e359-e366.	4.6	4
177	Common congenital heart problems in acute and intensive care. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2023, 12, 267-279.	1.0	0
178	Low D-dimer levels at diagnosis of venous thromboembolism are associated with reduced risk of recurrence: data from the TROLL registry. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 1861-1868.	3.8	1
179	Risk Factors, Clinical Presentation, Therapeutic Trends, and Outcomes in Arterial Thrombosis Complicating Unvaccinated COVID-19 Patients: A Systematic Review. <i>Angiology</i> , 0, , 000331972311670.	1.8	1
180	Editor's Choice "European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases. <i>European Journal of Vascular and Endovascular Surgery</i> , 2023, 65, 627-689.	1.5	29
181	Long-term outcome of chronic thromboembolic pulmonary hypertension using direct oral anticoagulants and warfarin: a Japanese prospective cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 2151-2162.	3.8	5
182	Initiative to reduce inappropriate venous thromboembolism prophylaxis in an 11â€œhospital safety net system: An electronic health recordsâ€œbased approach. <i>Journal of Hospital Medicine</i> , 0, , .	1.4	0
183	Comparative outcomes of anticoagulation alone versus anticoagulation plus endovascular intervention in adults with isolated renal vein thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2023, 11, 816-823.	1.6	5
184	THROMBOLYSIS IN PULMONARY EMBOLISM TREATMENT. <i>Wiadomości Lekarskie</i> , 2023, 76, 604-609.	0.3	0
185	Prolonged Fasting as a Cause of Deep Vein Thrombosis: A Case Report. <i>TH Open</i> , 2023, 07, e94-e96.	1.4	1
186	Mental Health and Quality of Life in Pulmonary Embolism: A Literature Review. <i>Advances in Respiratory Medicine</i> , 2023, 91, 174-184.	1.0	2
187	The hazard of therapeutic doses of anticoagulants in patients with isolated subsegmental pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 0, , .	2.1	0
188	SAMe-TT₂R₂ to Predict Clinical Outcomes and Time in Therapeutic Range in Patients on Vitamin K Antagonists: A Systematic Review and Meta-Analysis. <i>Annals of Pharmacotherapy</i> , 2024, 58, 126-139.	1.9	2
190	Hemostatic defects in congenital disorders of glycosylation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 100142.	2.3	3
192	Direct-Acting Oral Anticoagulant Therapy in Cancer Patientsâ€œA Review. <i>Cancers</i> , 2023, 15, 2697.	3.7	1
193	Home treatment versus early discharge for the outpatient management of acute pulmonary embolism: A non-interventional, post-hoc cohort analysis. <i>Thrombosis Research</i> , 2023, 227, 25-33.	1.7	1
194	Trauma Patients With Cirrhosis Have a Similar Risk of Unplanned Operation and Decreased Associated Risk of Mortality With Venous Thromboembolism Chemoprophylaxis. <i>American Surgeon</i> , 0, , 000313482311779.	0.8	0
195	Oral anticoagulation therapy in the treatment of pulmonary thromboembolism. , 2023, 2, 62-66.		0

#	ARTICLE	IF	CITATIONS
196	What Surgeons Need to Know About the Recent Updates to the CHEST Guidelines on Antithrombotic Therapy for Venous Thromboembolic Disease and Perioperative Management of Antithrombotic Therapy. <i>Annals of Surgery</i> , 0, Publish Ahead of Print, .	4.2	1
197	Timing and Predictors of Recanalization After Anticoagulation in Cerebral Venous Thrombosis. <i>Journal of Stroke</i> , 2023, 25, 291-298.	3.2	2
198	Common Practice in the Treatment of Superficial Vein Thrombosis Involving the Sapheno-Femoral Junction: Results from a National Survey of the Italian Society of Angiology and Vascular Medicine (SIAPAV). <i>Medicina (Lithuania)</i> , 2023, 59, 1068.	2.0	1
199	Stenting or angioplasty for the treatment of deep vein thrombosis: Systematic review and meta-analysis of randomized controlled trials. <i>Medicine (United States)</i> , 2023, 102, e33924.	1.0	3
200	Prognosis of incidental pulmonary embolism vs. symptomatic pulmonary embolism in cancer patients: a single-center retrospective cohort study in China. <i>Thrombosis Journal</i> , 2023, 21, .	2.1	1
201	Tenecteplase: A Review of Its Pharmacology and Uses. <i>AACN Advanced Critical Care</i> , 2023, 34, 77-83.	1.1	0
202	Mediastinal hematoma following thrombolysis for acute pulmonary thromboembolism. <i>Respirology Case Reports</i> , 2023, 11, .	0.6	0
203	Interventional Cardio-Oncology: Unique Challenges and Considerations in a High-Risk Population. <i>Current Treatment Options in Oncology</i> , 2023, 24, 1071-1087.	3.0	1
204	Trends in Treatment Patterns and Outcomes of Patients With Pulmonary Embolism in Japan, 2010 to 2020: A Nationwide Inpatient Database Study. <i>Journal of the American Heart Association</i> , 2023, 12, .	3.7	0
205	Multimodality imaging in marantic endocarditis associated with cancer: a multicentric cohort study. <i>European Heart Journal Cardiovascular Imaging</i> , 0, , .	1.2	3
206	Clinical characteristics and dosing of apixaban and rivaroxaban for the management of venous thromboembolism: A multi-center retrospective observational study. <i>Saudi Pharmaceutical Journal</i> , 2023, 31, 101673.	2.7	0
207	The value of distinguishing patients with isolated subsegmental pulmonary embolism presenting to two tertiary hospitals in Australia: an observational study. <i>Journal of Thrombosis and Thrombolysis</i> , 0, , .	2.1	0
208	How I Treat: The approach to Prevention and Treatment of Thrombotic Complications in Hospitalized Patients. <i>Blood</i> , 0, , .	1.4	0
209	Low-dose apixaban or rivaroxaban as secondary prophylaxis of upper extremity deep vein thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2023, 56, 323-326.	2.1	1
210	Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2023, 50, 365-376.	1.8	1
211	Delphi Consensus on Reporting Standards in Clinical Studies for Endovascular Treatment of Acute Iliofemoral Venous Thrombosis and Chronic Iliofemoral Venous Obstruction. <i>Circulation: Cardiovascular Interventions</i> , 2023, 16, .	3.9	1
212	Fibrin Clot Properties in Cancer: Impact on Cancer-Associated Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2024, 50, 402-412.	2.7	0
213	Special Populations: Pulmonary Embolism and Heparin-Induced Thrombocytopenia and Thrombosis. , 2023, , 1-13.		0

#	ARTICLE	IF	CITATIONS
214	Long term follow-up of a multicentre cohort of COVID-19 patients with pulmonary embolism: Anticoagulation management and outcomes. <i>Thrombosis Research</i> , 2023, 229, 73-76.	1.7	3
215	Endovascular Treatment in Patients with Deep Venous Thrombosis. <i>Flebologiya</i> , 2023, 17, 101.	1.0	2
216	A Case of Pulmonary Tumor Thrombotic Microangiopathy Caused by Metastatic Ovarian Cancer: An Antemortem Diagnosis with Pulmonary Aspiration Cytopathology. <i>Internal Medicine</i> , 2023, , .	0.7	0
217	Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease. <i>American Journal of Cardiovascular Drugs</i> , 2023, 23, 247-255.	2.2	0
218	Mesenteric venous thrombosis. <i>Medicina Clínica (English Edition)</i> , 2023, 160, 400-406.	0.2	1
219	Percutaneous Cardiac Chambers and Pulmonary Artery Aspiration. <i>Current Cardiology Reports</i> , 2023, 25, 681-691.	2.9	2
220	Safety and mortality outcomes for direct oral anticoagulants in renal transplant recipients. <i>PLoS ONE</i> , 2023, 18, e0285412.	2.5	0
222	Safety Profile and Effectiveness of Rivaroxaban for Patients With Venous Thromboembolism in Japan—Results From Post-Marketing Surveillance (XASSENT) —. <i>Circulation Journal</i> , 2023, , .	1.6	1
223	Reliability of Risk Assessment for Intra-Hospital Venous Thromboembolism: An Exploratory Cross-Sectional Study. <i>Journal of Multidisciplinary Healthcare</i> , 0, Volume 16, 1541-1547.	2.7	0
224	Low Molecular Weight Heparin Treatment Patterns and Outcomes in Cancer Patients with Acute Venous Thromboembolism: A Nationwide Cohort Study in France. <i>Cancers</i> , 2023, 15, 3011.	3.7	2
225	Cancer-associated thromboembolism. <i>Intervencni A Akutni Kardiologie</i> , 2023, 22, 74-78.	0.0	0
226	Right heart thrombus in transit and peripherally inserted central catheters. <i>Thrombosis Journal</i> , 2023, 21, .	2.1	1
228	Indefinite Anticoagulant Therapy for First Unprovoked Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 2023, 176, 949-960.	3.9	1
229	Unprovoked Venous Thromboembolism. <i>Medical Clinics of North America</i> , 2023, , .	2.5	1
230	Use of patient-reported outcome measures in patients with venous thromboembolism: communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 2953-2962.	3.8	1
231	Evaluation of the inappropriate prescribing practices of rivaroxaban and their association with bleeding in tertiary care hospitals in Saudi Arabia. , 2023, 2, 48.		0
232	Safety and efficacy of apixaban versus low-molecular weight heparin or vitamin-K antagonists for venous thromboembolism treatment in patients with severe renal failure: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2023, 229, 77-85.	1.7	2
233	A majority of trauma-related deep venous thromboses resolve prior to discharge. <i>Journal of Thrombosis and Thrombolysis</i> , 0, , .	2.1	0

#	ARTICLE	IF	CITATIONS
234	High-Risk Pulmonary Embolism: Management for the Intensivist. <i>Journal of Intensive Care Medicine</i> , 2023, 38, 1087-1098.	2.8	2
235	Patterns and persistence of anticoagulant use in the treatment of venous thromboembolism: insights from South Korea. <i>Thrombosis and Haemostasis</i> , 0, , .	3.4	1
237	The clinical outcomes of different doses of rivaroxaban in patients with isolated distal deep vein thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2024, 12, 101653.	1.6	0
238	Management of an unintentional enoxaparin overdose: A case report and literature review. <i>American Journal of Health-System Pharmacy</i> , 0, , .	1.0	0
239	Comparison of day surgery between varicose veins with and without superficial venous thrombosis below knee: a propensity score-matched analysis. <i>BMC Cardiovascular Disorders</i> , 2023, 23, .	1.7	0
241	Venous thromboembolism prophylaxis for hospitalized adult patients: a survey of US health care providers on attitudes and practices. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 102168.	2.3	1
242	Automating venous thromboembolism risk assessment: a dual-branch deep learning method using electronic medical records. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	1
243	Anticoagulation strategies and long-term recurrence in patients with venous thromboembolism in the era of direct oral anticoagulants. <i>European Journal of Internal Medicine</i> , 2023, 118, 59-72.	2.2	6
244	Six-Month Outcomes of Mechanical Thrombectomy for Treating Deep Vein Thrombosis: Analysis from the 500-Patient CLOUT Registry. <i>CardioVascular and Interventional Radiology</i> , 2023, 46, 1571-1580.	2.0	8
245	Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism. <i>JAMA Network Open</i> , 2023, 6, e2328033.	5.9	3
247	Acute venous thromboembolism in patients with brain cancer: clinical course. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 102172.	2.3	1
248	Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the Jâ€™xactly study. <i>Thrombosis Journal</i> , 2023, 21, .	2.1	0
249	Suboptimal Use of DOACs Post-Discharge for Geriatric Hip Fractures with Isolated Calf Deep Vein Thrombosis: Do Clinician Prescribing Preferences and Patient Compliance Alters Clinical Outcomes?. <i>Clinical Interventions in Aging</i> , 0, Volume 18, 1423-1436.	2.9	0
250	Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial. <i>Circulation</i> , 2023, 148, 1665-1676.	1.6	7
252	The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2024, 12, 101670.	1.6	11
253	The Role of Biomarkers, Metabolomics, and COVID-19 in Venous Thromboembolismâ€™A Review of Literature. <i>International Journal of Molecular Sciences</i> , 2023, 24, 13411.	4.1	0
254	The importance of assessing the safe and effective use of oral anticoagulants in older adults. <i>Journal of the American Geriatrics Society</i> , 2023, 71, 3954-3956.	2.6	0
255	Antiphospholipid Syndrome: State of the Art of Clinical Management. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	2.6	1

#	ARTICLE	IF	CITATIONS
256	Breaking down tumor thrombus: Current strategies for medical management. <i>Thrombosis Research</i> , 2023, 230, 144-151.	1.7	0
257	The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2023, 64, 102194.	7.1	2
258	High systemic inflammation response index level is associated with an increased risk of lower extremity deep venous thrombosis: a large retrospective study. <i>Annals of Medicine</i> , 2023, 55, .	3.8	1
259	Prevalence of and Eligibility for Surveillance Without Anticoagulation Among Adults With Lower-Risk Acute Subsegmental Pulmonary Embolism. <i>JAMA Network Open</i> , 2023, 6, e2326898.	5.9	0
260	Prevention, Diagnostics and Treatment of Deep Vein Thrombosis. Russian Experts Consensus. <i>Flebologiya</i> , 2023, 17, 152.	1.0	6
261	A Novel Risk Prediction Score for Clinically Significant Bleeding in Patients Anticoagulated for Venous Thromboembolism with Active Cancer. <i>Thrombosis and Haemostasis</i> , 0, , .	3.4	2
263	Comparative outcomes of catheter-directed thrombolysis versus AngioJet pharmacomechanical catheter-directed thrombolysis for treatment of acute iliofemoral deep vein thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2024, 12, 101669.	1.6	2
264	Assessing outcomes after thrombectomy with or without iliac vein stenting for young provoked DVT patients with iliac vein stenosis. <i>Thrombosis Journal</i> , 2023, 21, .	2.1	0
265	Thromboembolic prophylaxis in neurosurgical practice: a systematic review. <i>Acta Neurochirurgica</i> , 0, , .	1.7	0
266	Unresolved issues in the use of direct acting oral anticoagulants. <i>Expert Review of Cardiovascular Therapy</i> , 2023, 21, 913-921.	1.5	0
267	Below the knee, let it be: Management of calf DVT in hospitalized trauma patients. <i>American Journal of Surgery</i> , 2023, , .	1.8	0
268	Congenital thrombophilia in East-Asian venous thromboembolism population: a systematic review and meta-analysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 102157.	2.3	3
269	Prognostication of Patients with Pulmonary Thromboembolism with and without Residual Deep Vein Thrombosis: A Subanalysis of the Jâ€™xactly Study. <i>Annals of Vascular Diseases</i> , 2023, 16, 181-188.	0.5	2
270	Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 3649-3657.	3.8	5
271	Special Populations: Pulmonary Embolism and Heparin-Induced Thrombocytopenia and Thrombosis. , 2023, , 1-13.		0
272	Long-Term Medical Management. , 2023, , 307-313.		0
273	A Comparison of the Caprini Score With an Institutional Risk Assessment Tool for Prediction of Venous Thromboembolism After Total Joint Arthroplasty at an Urban Tertiary Care Health Safety Net Hospital. <i>Arthroplasty Today</i> , 2023, 23, 101194.	1.6	0
274	Assessment of effectiveness and safety of thrombolytic therapy to pulmonary emboli by endobronchial ultrasound-guided transbronchial needle injection. <i>JTCVS Techniques</i> , 2023, , .	0.4	0

#	ARTICLE	IF	CITATIONS
275	Indigo [®] Aspiration System for thrombectomy in pulmonary embolism. Future Cardiology, 2023, 19, 469-475.	1.2	0
277	Comparative efficacy and safety of measures for the treatment of adults with isolated calf muscular vein thrombosis: a systematic review and network meta-analysis. Annals of Vascular Surgery, 2023, , .	0.9	0
278	Known Unknowns in the Contemporary Management of High-Risk Pulmonary Embolism. Interventional Cardiology Clinics, 2023, , .	0.4	0
279	Anticoagulation in cancer-associated thrombosis: how long should the therapy be?. European Heart Journal - Cardiovascular Pharmacotherapy, 0, , .	3.0	0
280	Meta-Analysis Comparing Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients With Chronic Thromboembolic Pulmonary Hypertension. American Journal of Cardiology, 2024, 210, 172-176.	1.6	1
281	Cost-Comparison of Mechanical Thrombectomy and Catheter-Directed Thrombolysis in Intermediate-Risk Pulmonary Embolism. , 2024, 3, 101187.		0
282	The Early Initiation of Perioperative Anticoagulation Therapy in Cirrhotic Patients with Portal Hypertension After Laparoscopic Splenectomy Plus Esophagogastric Devascularization: A 10-Year Single-Center Experience. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 0, , .	1.0	0
283	Removing infrarenal inferior vena cava filters (IVCFs) with thrombus under protection of suprarenal IVCFs: A retrospective study in a single-center institution. Medicine (United States), 2023, 102, e35574.	1.0	0
286	Coagulation-monitored, dose-adjusted catheter-directed thrombolysis or pharmaco-mechanical thrombus removal in deep vein thrombosis. Vasa - European Journal of Vascular Medicine, 0, , .	1.4	0
287	Guideline Compliance and Indications for Inferior Vena Cava Filter Placement at a Quaternary Care Medical Center. Journal of Endovascular Therapy, 0, , .	1.5	0
288	The clinical application of venous ultrasound in diagnosis and follow-up of lower extremity deep vein thrombosis (DVT): a case-based discussion. Thrombosis Journal, 2023, 21, .	2.1	0
289	Global Research Hotspots in Venous Thromboembolism Anticoagulation: A Knowledge-Map Analysis from 2012 to 2021. Journal of Interventional Cardiology, 2023, 2023, 1-13.	1.2	0
290	Case report: hunting the hidden: surgical treatment of chronic silent thrombus in the left ventricle in a young alcoholic patient with myocardial bridging. Journal of Cardiothoracic Surgery, 2023, 18, .	1.1	0
291	Provoked vs minimally provoked vs unprovoked VTE: does it matter?. Hematology American Society of Hematology Education Program, 2023, 2023, 600-605.	2.5	1
292	Management of isolated distal deep venous thrombosis. Phlebology, 2024, 39, 143-146.	1.2	0
293	Comparing U.S. and Canadian treatment patterns on venous thromboembolism outcomes in the GARFIELD-VTE registry. Thrombosis Research, 2023, 232, 123-132.	1.7	0
294	Use of direct oral anticoagulants and low molecular weight heparin in venous thromboembolism associated with cancer: real-world evidence in Argentina. Expert Review of Hematology, 2023, 16, 1143-1149.	2.2	0
295	Management and outcomes of superficial vein thrombosis: a single-center retrospective study. Research and Practice in Thrombosis and Haemostasis, 2024, 8, 102263.	2.3	0

#	ARTICLE	IF	CITATIONS
296	Verl�ngerte medikament�se Sekund�rprophylaxe ven�ser Thromboembolien (VTEs). Springer Reference Medizin, 2023, , 1-5.	0.0	0
297	Treatment Patterns of Cancer-associated Thrombosis in the Netherlands: The Four Cities Study. TH Open, 2024, 08, e61-e71.	1.4	0
298	Important Considerations in the Intensive Care Management of Acute Leukemias. Journal of Intensive Care Medicine, 2024, 39, 291-305.	2.8	0
299	Catheter�based therapy for intermediate or high�risk pulmonary embolism is associated with lower in�hospital mortality in patients with cancer: Insights from the National Inpatient Sample. Catheterization and Cardiovascular Interventions, 2024, 103, 348-358.	1.7	1
300	Risikofaktoren f�r Rezidive ven�ser Thromboembolien (VTE). Springer Reference Medizin, 2023, , 1-11.	0.0	0
301	Comparison of clinical outcomes among patients with isolated axial vs muscular calf vein thrombosis: A systematic review and meta-analysis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2024, 12, 101727.	1.6	1
302	Real life results of direct-acting oral anticoagulants recommended-dose in obese vs normal-weight patients with venous thromboembolism. Thrombosis Research, 2024, 233, 165-172.	1.7	0
303	Describing Lower Limb Deep Vein Thrombosis: Needs More Than Just the Knee. , 2023, , 339-341.		0
304	How to manage splanchnic vein thrombosis in patients with liver disease. Hematology American Society of Hematology Education Program, 2023, 2023, 281-288.	2.5	1
305	Trends and outcomes of lytic-based therapies for high-risk pulmonary embolism: A nationwide analysis. Vascular Medicine, 2024, 29, 26-35.	1.5	0
306	Long-term outcomes of endovascular treatment of acute lower limb deep-vein thrombosis combined with May�Thurner syndrome: A single-center retrospective cohort study. Vascular Investigation and Therapy, 2023, 6, 67.	0.3	0
307	Discharge from the emergency department and outpatient clinic in cancer patients with acute symptomatic and incidental pulmonary embolism: A multicenter retrospective cohort study. Thrombosis Research, 2024, 233, 181-188.	1.7	0
308	Physiologically based pharmacokinetic modeling of apixaban to predict exposure in populations with hepatic and renal impairment and elderly populations. European Journal of Clinical Pharmacology, 2024, 80, 261-271.	1.9	0
309	Acute Nonvariceal Upper Gastrointestinal Bleeding in Patients Using Anticoagulants: Does the Timing of Endoscopy Affect Outcomes?. Digestive Diseases and Sciences, 2024, 69, 570-578.	2.3	0
310	Clinical Characteristics and Outcomes of Patients With Venous Thromboembolism Receiving Edoxaban in the Real World. Circulation Journal, 2024, 88, 371-379.	1.6	1
311	Primary Care Clinicians� Prescribing Patterns of Reduced-Dose Direct Oral Anticoagulants for Extended-Phase Venous Thromboembolism Treatment. Journal of Clinical Medicine, 2024, 13, 96.	2.4	0
312	A Nomogram Model to Predict Deep Vein Thrombosis Risk After Surgery in Patients with Hip Fractures. Indian Journal of Orthopaedics, 2024, 58, 151-161.	1.1	0
313	Cancer-associated splanchnic vein thrombosis: Clinical implications and management considerations. Thrombosis Research, 2024, 234, 75-85.	1.7	1

#	ARTICLE	IF	CITATIONS
314	Age-Related Differences in the Presentation, Management, and Clinical Outcomes of 100,000 Patients With Venous Thromboembolism in the RIETE Registry. <i>Archivos De Bronconeumologia</i> , 2024, 60, 143-152.	0.8	0
315	External validation of the PE-SARD risk score for predicting early bleeding in acute pulmonary embolism in the RIETE Registry. <i>Thrombosis Research</i> , 2024, 235, 22-31.	1.7	0
316	Endovenous laser ablation of great saphenous vein and pharmacotherapy of acute ascending thrombophlebitis: results of a three-month follow-up. <i>Rational Pharmacotherapy in Cardiology</i> , 2023, 19, 542-548.	0.8	0
317	Geographical and ethnoracial differences in venous thromboembolism and anticoagulation: An expanding horizon. <i>European Journal of Internal Medicine</i> , 2023, 118, 43-45.	2.2	1
318	Cancer-associated venous thromboembolism in the direct oral anticoagulants era: Insight from the COMMAND VTE Registry-2. <i>Thrombosis Research</i> , 2024, 234, 86-93.	1.7	0
319	Risk Stratification and Management of Intermediate-Risk Acute Pulmonary Embolism. <i>Journal of Clinical Medicine</i> , 2024, 13, 257.	2.4	0
320	Safety and Efficacy of Reduced-Dose Versus Full-Dose Alteplase for Acute Pulmonary Embolism: A Multicenter Observational Comparative Effectiveness Study*. <i>Critical Care Medicine</i> , 2024, 52, 729-742.	0.9	1
321	Direct-Acting Oral Anticoagulants in patients at extremes of body weight: a review of pharmacological considerations and clinical implications. <i>TH Open</i> , 2024, 08, e31-e41.	1.4	0
322	Correspondence and comments on American College of Rheumatology and EULAR antiphospholipid syndrome classification criteria: comment on the article by Barbhaiya et al. <i>Arthritis and Rheumatology</i> , 2024, 76, 816-817.	5.6	1
323	DOACs for the Medical Management of Venous Thromboembolism in Adults. , 0, , .		0
324	Balancing the risks of recurrent venous thromboembolism and bleeding with extended anticoagulation: oh, for a crystal ball!. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2024, 8, 102316.	2.3	0
325	Anticoagulation in Patients with Isolated Distal Deep Vein Thrombosis: Bringing the Puzzle Together. <i>Thrombosis and Haemostasis</i> , 0, , .	3.4	0
326	SAMe-TT2R2 Score to Predict Time in Therapeutic Range of Vitamin K Antagonists in Asian and Non-Asian patients: A Systematic Review and Meta-analysis. <i>American Journal of Cardiovascular Drugs</i> , 2024, 24, 211-240.	2.2	0
327	Hybrid Thrombectomy and Central Extracorporeal Membrane Oxygenation for Massive Pulmonary Embolism in a Child. <i>World Journal for Pediatric & Congenital Heart Surgery</i> , 0, , .	0.8	0
328	Transition of management strategies and long-term outcomes in cancer-associated venous thromboembolism from the warfarin era to the direct oral anticoagulant era. <i>European Journal of Internal Medicine</i> , 2024, 123, 72-80.	2.2	2
329	Payer approval and rejection of oral anticoagulant prescriptions and prescription abandonment patterns among patients with venous thromboembolism. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2024, 30, 441-455.	0.9	0
330	Anticoagulant prescribing patterns in patients with primary central nervous system malignancies and secondary metastases. <i>Journal of Thrombosis and Thrombolysis</i> , 2024, 57, 418-427.	2.1	0
331	Things We Do for No ReasonTM: Dose adjusting apixaban in acute kidney injury. <i>Journal of Hospital Medicine</i> , 0, , .	1.4	0

#	ARTICLE	IF	CITATIONS
332	Edoxaban versus warfarin in chronic thromboembolic pulmonary hypertension. , 0, , .		0
334	Efficacy and safety of anticoagulant for treatment and prophylaxis of VTE patients with renal insufficiency: a systemic review and meta-analysis. Thrombosis Journal, 2024, 22, .	2.1	0
335	Use of Ultrasound-Assisted, Catheter-Directed Thrombolysis in a Patient With High-Risk Pulmonary Embolism. Texas Heart Institute Journal, 2024, 51, .	0.3	0
336	Morbidity Following Pulmonary Embolism Hospitalization- Contributing Factors and Outcomes. Journal of Cardiothoracic and Vascular Anesthesia, 2024, 38, 1239-1243.	1.3	0
339	Endovenous laser ablation and drug treatment of acute great saphenous vein ascending thrombophlebitis: comparison of three approaches to the treatment of patients. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 22, 3863.	1.4	0
340	The impact of factor Xa inhibitors on bleeding risk in patients with respiratory diseases. Scientific Reports, 2024, 14, .	3.3	0
341	Superficial Venous Thrombosis: A Comprehensive Review. Healthcare (Switzerland), 2024, 12, 500.	2.0	0
342	Antithrombotische Therapie. , 2023, , 255-287.		0
343	A systematic review of therapeutic enoxaparin dosing in obesity. Journal of Thrombosis and Thrombolysis, 2024, 57, 587-597.	2.1	0
344	Subsegmental Pulmonary Emboli and Chronic Pulmonary Emboli Should Not Be Ignored. Radiology, 2024, 310, .	7.3	0
345	Comparative Effectiveness and Safety of Direct Oral Anticoagulants Compared with Warfarin in Patients with Low Bodyweight who have Atrial Fibrillation: AASystematic Review and Meta-analysis. American Journal of Cardiovascular Drugs, 2024, 24, 255-271.	2.2	0
346	Development and Validation of a Natural Language Processing Model to Identify Low-Risk Pulmonary Embolism in Real Time to Facilitate Safe Outpatient Management. Annals of Emergency Medicine, 2024, , .	0.6	0
347	Intermediate-Risk Acute Pulmonary Embolism. Chest, 2024, 165, 484-485.	0.8	0
348	Embolism-Threatening Thrombosis: Is There Such a Problem?. Flebologiya, 2024, 18, 38.	1.0	0
349	Tailored anticoagulant treatment after a first venous thromboembolism: protocol of the Leiden Thrombosis Recurrence Risk Prevention (L-TRRiP) study - cohort-based randomised controlled trial. BMJ Open, 2024, 14, e078676.	1.9	0
350	Comparison of Treatment Approaches and Subsequent Outcomes within a Pulmonary Embolism Response Team Registry. Critical Care Research and Practice, 2024, 2024, 1-17.	1.1	0
351	Incidental deep venous thrombosis diagnosed on lower extremity computed tomography is a rare but clinically impactful finding. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2024, 12, 101858.	1.6	0
352	Association of pathologic factors with postoperative venous thromboembolism after gastrointestinal cancer surgery. Journal of Gastrointestinal Surgery, 2024, , .	1.7	0

#	ARTICLE	IF	CITATIONS
353	Unlocking the potential of fondaparinux: guideline for optimal usage and clinical suggestions (2023). Frontiers in Pharmacology, 0, 15, .	3.5	0
354	Ultrasound-Assisted Catheter-Directed Thrombolysis for the Management of Pulmonary Embolism: <i>A Single Center Experience in a Community Hospital</i>. Journal of Cardiovascular Pharmacology and Therapeutics, 2024, 29, .	2.0	0
355	European expert consensus recommendations on the primary care use of direct oral anticoagulants in patients with venous thromboembolism. , 2024, 25, .		0
356	Venous Thromboembolism Management throughout the COVID-19 Era: Addressing Acute and Long-Term Challenges. Journal of Clinical Medicine, 2024, 13, 1825.	2.4	0
357	Fibrinolytic Agents in Thromboembolic Diseases: Historical Perspectives and Approved Indications. Seminars in Thrombosis and Hemostasis, 0, , .	2.7	0